Below we provide an update on several ophthalmic anti-VEGF therapeutics currently being studied in clinical trials.

EYLEA® HD (Aflibercept, 8 mg)

Regeneron announced positive two-year (96 weeks) results from its PULSAR trial investigating Eylea® HD (aflibercept, 8 mg) with 12- and 16-week dosing regimens compared to EYLEA® (aflibercept, 2 mg) in patients with wet AMD.